Maintaining Evidence-based Opioid Agonist Treatment During a Methadone to Buprenorphine Rotation With Slow-release Oral Morphine

被引:1
作者
Costa, Tianna [1 ]
Hannah, Madelynn [1 ]
Cuperfain, Ari [2 ]
Chopra, Nitin [1 ,2 ]
机构
[1] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON, Canada
[2] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
关键词
opioid use disorder; opioid agonist treatment; methadone; buprenorphine-naloxone; slow release oral morphine; TRANSITION;
D O I
10.1097/CXA.0000000000000168
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Patients may transition from methadone to buprenorphine-naloxone for various reasons. Alternative methods to ease this transition have been reported in the literature including low-dose buprenorphine (microdosing) and using slow-release oral morphine (SROM). We present the case of a 34-year-old male presenting to the hospital with stimulant-induced psychosis, wishing to transition from methadone to buprenorphine. Given the long and variable half-life of methadone, a wash-out period of at least 5 days is recommended to avoid precipitated withdrawal, before starting buprenorphine-naloxone. This can be a high-risk period if a patient decided to leave against medical advice during the transition. To reduce withdrawal symptoms during this period and to maintain the patient on opioid agonist treatment, SROM was started the day after methadone was discontinued. SROM and immediate-release morphine PRN were increased every 1-2 days (maximum dose of 570 mg daily) and on day 6, a rapid induction of buprenorphine-naloxone was initiated. In 3 days, he stabilized on 32 mg and continued on this dose for the remainder of his hospitalization. He later transitioned to buprenorphine extended-release injection. This case highlights an approach to facilitate transitioning from methadone to buprenorphine-naloxone and subsequently buprenorphine extended-release injection that prioritizes patient comfort and treatment retention, maintaining the use of evidence-based opioid agonist therapy throughout treatment.
引用
收藏
页码:15 / 18
页数:4
相关论文
共 8 条
[1]   Management of opioid use disorders: a national clinical practice guideline [J].
Bruneau, Julie ;
Ahamad, Keith ;
Goyer, Marie-Eve ;
Poulin, Ginette ;
Selby, Peter ;
Fischer, Benedikt ;
Wild, T. Cameron ;
Wood, Evan .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2018, 190 (09) :E247-E257
[2]  
Centre for Addiction and Mental Health, 2021, OP AG THER SYNTH CAN
[3]   Exploring Slow Release Oral Morphine (SROM) As a Transition Bridge for Medium to High Doses of Methadone Conversion to Buprenorphine/Naloxone Sublingual: A Calgary Concept and Approach [J].
Ghosh, S. Monty ;
Vezina, Lydia ;
Yu, Alvis ;
Jariwala, Abhishek ;
Lim, Ronald ;
Tanguay, Robert .
CANADIAN JOURNAL OF ADDICTION, 2019, 10 (02) :18-24
[4]   A Review of Novel Methods To Support The Transition From Methadone and Other Full Agonist Opioids To Buprenorphine/Naloxone Sublingual In Both Community and Acute Care Settings [J].
Ghosh, Sumantra Monty ;
Klaire, Sukhpreet ;
Tanguay, Robert ;
Manek, Mandy ;
Azar, Pouya .
CANADIAN JOURNAL OF ADDICTION, 2019, 10 (04) :41-50
[5]  
Government of Canada, 2022, Surveillance of Opioidand StimulantRelated Harms in Canada Apparent Opioid and Stimulant Toxicity Deaths
[6]   Tackling the overdose crisis: The role of safe supply [J].
Ivsins, Andrew ;
Boyd, Jade ;
Beletsky, Leo ;
McNeil, Ryan .
INTERNATIONAL JOURNAL OF DRUG POLICY, 2020, 80
[7]  
National Institute on Drug Abuse, 2022, OV DEATH RAT
[8]   Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada [J].
Young, Samantha ;
Kolla, Gillian ;
McCormack, Daniel ;
Campbell, Tonya ;
Leece, Pamela ;
Strike, Carol ;
Srivastava, Anita ;
Antoniou, Tony ;
Bayoumi, Ahmed M. ;
Gomes, Tara .
INTERNATIONAL JOURNAL OF DRUG POLICY, 2022, 102